SGLT-2 Inhibitors and Their Potential in the Treatment of Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - New Zealand
doi 10.2147/dmso.s34416
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure

Metabolic Syndrome and Related Disorders
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

SGLT-2 Inhibitors – Are They to Stay?

Diabesity
2017English

Relationship Between Euglycemic Diabetic Ketoacidosis and SGLT-2 Inhibitors

Global Journal of Endocrinological Metabolism
2018English

The Potential Role of Sodium Glucose Co-Transporter 2 Inhibitors in the Early Treatment of Type 2 Diabetes Mellitus

International Journal of Clinical Practice
Medicine
2015English

Cardio‐renal Protective Effect of SGLT 2 Inhibitors and Mitochondrial Function

Journal of Diabetes Investigation
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2019English

Pdb13 - Systematic Literature Review and Network Meta-Analysis of SGLT-2 Inhibitors and Metformin as Add-On to Insulin for the Treatment of Type 1 Diabetes

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Antidepressant Activity of SGLT – 2 Inhibitors in Albinomice, an Experimental Study

International Journal of Dental Research & Development
2018English

Exploring the Heterogeneity of the Effects of SGLT-2 Inhibitors in Cardiovascular Outcome Trials

Nutrition, Metabolism and Cardiovascular Diseases
NutritionCardiologyEndocrinologyCardiovascular MedicineDieteticsMedicineMetabolismDiabetes
2020English

Incretin Mimetics and Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes

European Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy